TABLE 3

Impact of DAA on coadministered drug exposure (AUC)

Data are given in percentages.

Drug ClassSMPSOFLDV/SOFDCVOBV/PTV/DSV/rGZREBRSOF/VELSOF/VEL/VOXGLE/PIB
Immunosuppressants
 Cyclosporine↑482
 Everolimus↑2612
 Mycophenolic  acid
 Sirolimus↑3699
 Tacrolimus↓17↑5613↑43↑45
Statins
 Atorvastatin↑112↑94↑54↑728c
 Lovastatin↑70; lovastatin acid ↑310
 Pravastatin↑82↑33↑35↑116b↑130c
 Rosuvastatin↑181↑58↑159↑126↑169↑639b↑115c
 Simvastatin↑51; simvastatin acid ↑88↑132; simvastatin acid ↑348
Cardiovascular
 Amiodaronea
 Amlodipine↑157
 Dabigatran↑161b↑138
 Digoxin↑39↑16↑34↑48c
 Felodipine↑31
 Losartan↑56; losartan acid ↔
 Valsartan↑31
Antifungals
 Ketoconazole↑ 117
Acid-reducing agents
 Omeprazole↑21↓38↓21
Antibacterial agents
 Erythromycin↑90
 Rifampin
CNS agents
 Buprenorphine↑37 buprenorphine; ↑62 norbuprenorphine↑107 buprenorphine; ↑84 norbuprenorphine
 Hydrocodone↑90
 Methadone
 Midazolamp.o. ↑45; i.v. ↔↑27
Other
 OC (NGMN, norgestimate, EE, or LNG)↔ EE; ↔ NGMN; ↑19 NG↑20 EE; ↔ NGMN; ↔ NG↔ EE; ↑160 NGMN; ↑154 NG↔ EE, LNG↔EE, LNG↑28–40 EE; ↑44 NGMN; ↑63–68 NG
  • CNS, central nervous system; DCV, daclatasvir; DSV, dasabuvir; EBR, elbasvir; GLE, glecaprevir; GZR, grazoprevir; LDV, ledipasvir; LNG, levonorgestrel; NG, norgestrel; NGMN, norelgestromin; OBV, ombitasvir; OC, oral contraceptive; PIB, pibrentasvir; PTV, paritaprevir; SMP, simeprevir; SOF, sofosbuvir; VEL, velpatasvir; VOX, voxilaprevir. ↑: increase in exposure; ↓: decrease in exposure; ↔: no change; —: data not available.

  • a Interactions with amiodarone not identified although adverse events have been observed during coadministration with DAAs.

  • b SOF/VEL/VOX plus VOX.

  • c 400/120 mg GLE/PIB daily.